Management of T3‑Predominant Thyrotoxicosis (Suppressed TSH, Elevated T3, Normal T4)

1. Diagnostic Confirmation

Repeat thyroid function tests to verify persistent TSH suppression (< 0.01 mU/L) with elevated total T3 and normal free T4 before initiating therapy, because transient abnormalities do not require treatment. 2
Use total T3 assays rather than free T3 because they have superior methodological reliability and are specifically recommended by the American Association of Clinical Endocrinologists for evaluating hyperthyroidism. [2][3]

Perform a radioactive iodine uptake (RAIU) scan and thyroid scintigraphy when clinical features do not clearly indicate Graves disease; diffuse uptake suggests Graves, focal uptake indicates toxic adenoma, heterogeneous uptake points to toxic multinodular goiter, and low uptake is typical of destructive thyroiditis. 4
Measure TSH‑receptor antibodies (TRAb) when Graves disease is suspected; a positive result has near‑100 % sensitivity and specificity and can obviate the need for RAIU scanning. 2

Assess cardiovascular risk immediately by checking resting heart rate, obtaining an ECG for atrial fibrillation, and evaluating heart‑failure symptoms, because T3 exerts more potent cardiac effects than T4. 4
Initiate β‑adrenergic blockade in any patient with resting heart rate > 90 bpm, age > 65 years, or any cardiovascular comorbidity to prevent arrhythmias and decompensation. 4
Recognize that elderly patients and those with free T3 levels 2–3 × the upper limit of normal are at highest risk for complications and therefore require urgent treatment. 4

Radioactive iodine (RAI) ablation is first‑line therapy, typically delivered as a single dose of 10–15 mCi to render the patient hypothyroid. 4
If T3 is markedly elevated (> 2–3 × ULN) or significant cardiovascular disease is present, pretreat with methimazole for 4–6 weeks before RAI, then discontinue methimazole 3–7 days prior to RAI administration. 4
Verify a negative pregnancy test within 48 hours before RAI in all women of child‑bearing potential. 4

Either RAI or surgery is appropriate; solitary toxic adenoma is usually treated with thyroid lobectomy, whereas toxic multinodular goiter is managed with near‑total thyroidectomy. 2
Surgical treatment may be preferred in younger patients or when large goiters cause compressive symptoms. 2

No antithyroid drugs are indicated because the condition is self‑limited and results from hormone release rather than overproduction. 2

Methimazole is the preferred antithyroid medication for virtually all patients, except during first‑trimester pregnancy, thyroid storm, or in cases of minor methimazole reactions. 4
Start methimazole at 10–30 mg daily based on the severity of T3 elevation; titrate the dose every 4–6 weeks according to free T4 and total T3 levels. 5
Long‑term antithyroid drug therapy is not recommended as definitive treatment, except in elderly or frail patients with limited life expectancy who cannot tolerate RAI or surgery. 2

Measure free T4 and total T3 1–2 months after RAI; if thyrotoxicosis persists, continue monitoring every 4–6 weeks until resolution or consider retreatment at 3–6 months. 5
Expect TSH to remain suppressed for 1–3 months after biochemical resolution; during this interval, rely primarily on free T4 and T3 for assessment. 5
Hypothyroidism usually develops 2–6 months after RAI; initiate levothyroxine when free T4 falls below the normal range or when symptomatic hypothyroidism appears, titrating dose based on free T4 rather than TSH initially. 5

Do not label elevated T3 as “subclinical hyperthyroidism”; this pattern represents overt T3 thyrotoxicosis that requires definitive therapy. 1
Never rely on TSH alone for initial diagnosis or early post‑treatment monitoring, because TSH suppression lags behind normalization of thyroid hormones by weeks to months. 5
Exclude potential assay interferences (e.g., amiodarone, high‑dose glucocorticoids, biotin supplementation, heterophile antibodies) that can produce spurious thyroid function results. 2
Do not order free T3 when TSH is normal; a normal TSH essentially excludes hyperthyroidism except in rare cases of TSH‑producing pituitary adenoma or thyroid hormone resistance. [3][6]